Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual

Lineage-based vaccine design is an attractive approach for eliciting broadly neutralizing antibodies (bNAbs) against HIV-1. However, most bNAb lineages studied to date have features indicative of unusual recombination and/or development. From an individual in the prospective RV217 cohort, we identified three lineages of bNAbs targeting the membrane-proximal external region (MPER) of the HIV-1 envelope. Antibodies RV217-VRC42.01, -VRC43.01, and -VRC46.01 used distinct modes of recognition and neutralized 96%, 62%, and 30%, respectively, of a 208-strain virus panel. All three lineages had modest levels of somatic hypermutation and normal antibody-loop lengths and were initiated by the founder virus MPER. The broadest lineage, VRC42, was similar to the known bNAb 4E10. A multimeric immunogen based on the founder MPER activated B cells bearing the unmutated common ancestor of VRC42, with modest maturation of early VRC42 intermediates imparting neutralization breadth. These features suggest that VRC42 may be a promising template for lineage-based vaccine design.

Citing Articles

Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview.

Boomgarden A, Upadhyay C Vaccines (Basel). 2025; 13(2).

PMID: 40006695 PMC: 11860913. DOI: 10.3390/vaccines13020148.

Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG.

Wieczorek L, Chang D, Sanders-Buell E, Zemil M, Martinez E, Schoen J Virol J. 2024; 21(1):148.

PMID: 38951814 PMC: 11218331. DOI: 10.1186/s12985-024-02394-y.

RAIN: machine learning-based identification for HIV-1 bNAbs.

Foglierini M, Nortier P, Schelling R, Winiger R, Jacquet P, ODell S Nat Commun. 2024; 15(1):5339.

PMID: 38914562 PMC: 11196741. DOI: 10.1038/s41467-024-49676-1.

RAIN: a Machine Learning-based identification for HIV-1 bNAbs.

Perez L, Foglierini M Res Sq. 2024; .

PMID: 38903123 PMC: 11188109. DOI: 10.21203/rs.3.rs-4023897/v1.

Affinity gaps among B cells in germinal centers drive the selection of MPER precursors.

Ray R, Schiffner T, Wang X, Yan Y, Rantalainen K, Lee C Nat Immunol. 2024; 25(6):1083-1096.

PMID: 38816616 PMC: 11147770. DOI: 10.1038/s41590-024-01844-7.

References

Kwong P, Mascola J . Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012; 37(3):412-25. PMC: 4706166. DOI: 10.1016/j.immuni.2012.08.012. View

Weaver G, Villar R, Kanekiyo M, Nabel G, Mascola J, Lingwood D . In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates. Nat Protoc. 2016; 11(2):193-213. PMC: 6956844. DOI: 10.1038/nprot.2016.009. View

Scherer E, Smith R, Simonich C, Niyonzima N, Carter J, Galloway D . Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog. 2014; 10(10):e1004461. PMC: 4199765. DOI: 10.1371/journal.ppat.1004461. View

Langer G, Cohen S, Lamzin V, Perrakis A . Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat Protoc. 2008; 3(7):1171-9. PMC: 2582149. DOI: 10.1038/nprot.2008.91. View

Moody M, Pedroza-Pacheco I, Vandergrift N, Chui C, Lloyd K, Parks R . Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodies. Sci Immunol. 2017; 1(1):aag0851. PMC: 5589960. DOI: 10.1126/sciimmunol.aag0851. View

Li M, Gao F, Mascola J, Stamatatos L, Polonis V, Koutsoukos M . Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005; 79(16):10108-25. PMC: 1182643. DOI: 10.1128/JVI.79.16.10108-10125.2005. View

Kulp D, Steichen J, Pauthner M, Hu X, Schiffner T, Liguori A . Structure-based design of native-like HIV-1 envelope trimers to silence non-neutralizing epitopes and eliminate CD4 binding. Nat Commun. 2017; 8(1):1655. PMC: 5698488. DOI: 10.1038/s41467-017-01549-6. View

Dennison S, Stewart S, Stempel K, Liao H, Haynes B, Alam S . Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J Virol. 2009; 83(19):10211-23. PMC: 2748034. DOI: 10.1128/JVI.00571-09. View

Musen M, Bean C, Cheung K, Dumontier M, Durante K, Gevaert O . The center for expanded data annotation and retrieval. J Am Med Inform Assoc. 2015; 22(6):1148-52. PMC: 5009916. DOI: 10.1093/jamia/ocv048. View

10.

Felsenstein J, Churchill G . A Hidden Markov Model approach to variation among sites in rate of evolution. Mol Biol Evol. 1996; 13(1):93-104. DOI: 10.1093/oxfordjournals.molbev.a025575. View

11.

Morris L, Chen X, Alam M, Tomaras G, Zhang R, Marshall D . Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One. 2011; 6(9):e23532. PMC: 3184076. DOI: 10.1371/journal.pone.0023532. View

12.

Doria-Rose N, Georgiev I, ODell S, Chuang G, Staupe R, McLellan J . A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol. 2012; 86(15):8319-23. PMC: 3421697. DOI: 10.1128/JVI.00696-12. View

13.

Saunders K, Wang L, Joyce M, Yang Z, Balazs A, Cheng C . Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol. 2015; 89(16):8334-45. PMC: 4524228. DOI: 10.1128/JVI.00908-15. View

14.

Robb M, Eller L, Kibuuka H, Rono K, Maganga L, Nitayaphan S . Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. N Engl J Med. 2016; 374(22):2120-30. PMC: 5111628. DOI: 10.1056/NEJMoa1508952. View

15.

Correia B, Ban Y, Holmes M, Xu H, Ellingson K, Kraft Z . Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure. 2010; 18(9):1116-26. DOI: 10.1016/j.str.2010.06.010. View

16.

MacLeod D, Choi N, Briney B, Garces F, Ver L, Landais E . Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity. 2016; 44(5):1215-26. PMC: 5003182. DOI: 10.1016/j.immuni.2016.04.016. View

17.

Haynes B, Fleming J, St Clair E, Katinger H, Stiegler G, Kunert R . Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005; 308(5730):1906-8. DOI: 10.1126/science.1111781. View

18.

Simek M, Rida W, Priddy F, Pung P, Carrow E, Laufer D . Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009; 83(14):7337-48. PMC: 2704778. DOI: 10.1128/JVI.00110-09. View

19.

Doria-Rose N, Joyce M . Strategies to guide the antibody affinity maturation process. Curr Opin Virol. 2015; 11:137-47. PMC: 4456294. DOI: 10.1016/j.coviro.2015.04.002. View

20.

Zhu J, Ofek G, Yang Y, Zhang B, Louder M, Lu G . Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci U S A. 2013; 110(16):6470-5. PMC: 3631616. DOI: 10.1073/pnas.1219320110. View